{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-007671","form_type":"8-K","ticker":"PAYS","cik":"0001496443","company_name":"Paysign, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.251982+00:00","generated_at":"2026-06-08T14:44:35.167059+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Paysign Q3 revenue up 17% to $12.4M; net income $1.1M; pharma revenue +142%","bullets":["Q3 total revenues $12.4M (+17% YoY); net income $1.1M, diluted EPS $0.02.","Adjusted EBITDA $2.3M (+22% YoY); plasma revenue +13%, pharma patient affordability revenue +142%.","Added 19 new plasma centers (462 total); avg revenue per plasma center per month $8,102 (+7.8% YoY).","Exited quarter with $9.9M unrestricted cash, zero debt; repurchased 75k shares for $150k.","FY2023 guidance reaffirmed: revenue $44-46M, Adj. EBITDA $6-7.5M; Q4 growth expected slightly above 17%."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-007671","json":"https://secwatch.observer/filing/0001683168-23-007671.json","markdown":"https://secwatch.observer/filing/0001683168-23-007671.md","text":"https://secwatch.observer/filing/0001683168-23-007671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496443/000168316823007671/0001683168-23-007671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496443/000168316823007671/paysign_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:44:35.167059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34a2d026e4810197dad844cf7d38c97b1debc786","claim":"Paysign, Inc. reported financial results for the fiscal quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, we issued a press release regarding our financial results for the fiscal quarter ended September 30, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496443/000168316823007671/0001683168-23-007671-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}